Business Description
Bioage Labs Inc
NAICS : 325411
SIC : 2836
ISIN : US09077V1008
Total Employee Number:
62Description
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 112.43 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 12.18 | |||||
Beneish M-Score | -0.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 54.5 | |||||
3-Year EPS without NRI Growth Rate | 54.5 | |||||
3-Year FCF Growth Rate | 52.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -5.67 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -42.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.88 | |||||
9-Day RSI | 24.08 | |||||
14-Day RSI | 27.71 | |||||
3-1 Month Momentum % | 42.36 | |||||
6-1 Month Momentum % | 27.78 | |||||
12-1 Month Momentum % | 489.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 17.19 | |||||
Quick Ratio | 17.19 | |||||
Cash Ratio | 16.59 | |||||
Days Sales Outstanding | 22.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -27.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1026.28 | |||||
Net Margin % | -912.26 | |||||
EBITDA Margin % | -907.12 | |||||
FCF Margin % | -850.57 | |||||
OCF Margin % | -845.83 | |||||
ROE % | -29.55 | |||||
ROA % | -27.51 | |||||
ROIC % | -318.48 | |||||
3-Year ROIIC % | -311.28 | |||||
ROC (Joel Greenblatt) % | -2452.55 | |||||
ROCE % | -29.17 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 40.73 | |||||
PB Ratio | 1.28 | |||||
Price-to-Tangible-Book | 1.28 | |||||
EV-to-EBIT | -1.85 | |||||
EV-to-Forward-EBIT | -1.26 | |||||
EV-to-EBITDA | -1.85 | |||||
EV-to-Forward-EBITDA | -1.47 | |||||
EV-to-Revenue | 16.79 | |||||
EV-to-Forward-Revenue | 24.97 | |||||
EV-to-FCF | -1.97 | |||||
| Price-to-Net-Current-Asset-Value | 1.55 | |||||
| Price-to-Net-Cash | 1.61 | |||||
Earnings Yield (Greenblatt) % | -54.05 | |||||
FCF Yield % | -17.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioage Labs Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 8.904 | ||
| EPS (TTM) (€) | -2.045 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 110.36 | ||
| 14-Day RSI | 27.71 | ||
| 14-Day ATR (€) | 1.029259 | ||
| 20-Day SMA (€) | 15.22875 | ||
| 12-1 Month Momentum % | 489.5 | ||
| 52-Week Range (€) | 3.64 - 22.16 | ||
| Shares Outstanding (Mil) | 45.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioage Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioage Labs Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 85 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 9.37 (+0.00%) | ||
| General meeting for 2026 | 2026-06-10 12:00 | 13.21 (+0.00%) | ||
| Goldman Sachs Global Healthcare Conference | 2026-06-08 14:40 | 14.37 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 15:45 | 13.97 (+0.00%) | ||
| BioAge R&D Day | 2026-05-08 12:30 | 15.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 15.40 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-16 15:00 | 13.90 (+1.02%) | ||
| Annual report for 2025 | 2026-03-24 | 16.40 (+1.86%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 16.40 (+1.86%) |
Show
Entries
Bioage Labs Inc Frequently Asked Questions
What is Bioage Labs Inc(FRA:Y7G)'s stock price today?
The current price of FRA:Y7G is €9.76. The 52 week high of FRA:Y7G is €22.16 and 52 week low is €3.64.
When is next earnings date of Bioage Labs Inc(FRA:Y7G)?
The next earnings date of Bioage Labs Inc(FRA:Y7G) is 2026-11-06 Est..
Does Bioage Labs Inc(FRA:Y7G) pay dividends? If so, how much?
Bioage Labs Inc(FRA:Y7G) does not pay dividend.
Press Release
Articles on Bioage Labs Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers